Company intelligence / Profile preview
RASRx
California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
RASRx1902 demonstrated improved muscle strength and regeneration while decreasing muscle inflammation, degeneration, and necrosis in preclinical studies[2]. The compound received Orphan Drug Designation from the FDA in June 2017[2].
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Southern California (technology licensor)CureDuchenne Ventures (investor)
Beyond the preview
Go deeper on RASRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RASRx.